antirejection therapy

antirejection therapy

(ant″i-rĕ-jek′shŏn) [ anti- + rejection]
Any of the drugs that suppress the immune system in patients who have undergone organ transplantation.

CAUTION!

These agents decrease the likelihood that the transplant recipient will react against the transplanted organ but increase the likelihood of some infectious diseases and cancers.
Mentioned in ?
References in periodicals archive ?
Antirejection therapy with high doses of corticosteroids could have exerted an additional important risk factor.
Patients receiving thymoglobulin antirejection therapy (3 cases) were fewer in the heated versus control group (13 cases; P=.
In these 6 cases, therefore, the AR diagnosis was based on clinical signs and symptoms, plasma creatinine concentrations, and a satisfactory response to empirical treatment with antirejection therapy.
described a high total Tr-DNA concentration in a patient with AR followed by a decrease in this marker after antirejection therapy (30).
7) In the posttransplant population, it is a well-known complication of antirejection therapy with cyclosporin A (8-10) and tacrolimus.
WASHINGTON -- The introduction of highly active antiretroviral therapy, more effective prophylactic regimens, and improvements in surgical technique and antirejection therapy have made solid organ transplantation a possibility for HIV-infected patients, said Marla J.
T lymphocytes in the third patient to indicate the degree of immunosuppression, since antirejection therapy had been administered 15 months before the occurrence of PCP.
The treatment was developed at the University of Pittsburgh (PA) using the hypothesis that delivering antirejection therapy directly into the lungs might provide greater protection for transplant recipients.
Among organ transplant recipients, salmonellosis is associated strongly with antirejection therapy (2), and febrile illness with bacteremia is a more common presentation (3).
Results from controlled clinical trials with renal transplant patients have shown that the addition of MMF to immunosuppression protocols with cyclosporine and steroids substantially reduces the early acute rejection rate and decreases the need for antirejection therapy while showing a favorable safety profile (6-8).